Pharmacological Ascorbate for Lung Cancer

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

55 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-04-30

Study Completion Date

2022-08-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This clinical trial evaluates adding high-dose ascorbate (vitamin C) to standard of care treatment of non-small cell lung cancer (NSCLC) in adults. All subjects will receive high-dose ascorbate in addition to the standard treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC

NCT02905591

Carcinoma, Non-Small-Cell Lung Non-Small Cell Lung Cancer Nonsmall Cell Lung Cancer +2 more

ACTIVE_NOT_RECRUITING PHASE2

Adjunctive Intravenous Ascorbic Acid for Advanced Non-Small Cell Lung Cancer

NCT05849129

Lung Cancer

RECRUITING PHASE2

Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease

NCT01125449

Sarcoma Adenocarcinoma Carcinoma +2 more

WITHDRAWN PHASE2

Trial of Chemotherapy Plus Intravenous Vitamin C in Patients With Advanced Cancer for Whom Chemotherapy Alone is Only Marginally Effective

NCT01050621

Cancer

COMPLETED PHASE1/PHASE2

Study of High-Dose Intravenous (IV) Vitamin C Treatment in Patients With Solid Tumors

NCT00441207

Cancer

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Standard treatment for non-small cell lung cancer (NSCLC) involves a combined therapy of paclitaxel and carboplatin. These drugs are administered once every 21 days. This study adds high dose ascorbic acid (75g per infusion) twice per week for up to 4 cycles of therapy.

Participants will:

* receive high doses of intravenous (IV) ascorbate two times a week during each 3 week chemotherapy.
* have blood samples drawn to measure blood ascorbate levels once every 21 days
* have blood samples drawn to measure iron and ferritin levels before treatment, then on cycles 1 and 3.

The active therapy portion of this study lasts for 4 months. After that is completed, participants will go back to standard therapy for their cancer. Participants will continue to have life-long follow-up for this study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Carcinoma, Non-Small-Cell Lung

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ascorbate, paclitaxel, carboplatin

Paclitaxel, administered once per cycle (3 weeks) Carboplatin, administered once per cycle (3 weeks) Pharmacological ascorbate (ascorbic acid) infusions, 2 times per week for 3 weeks

Group Type EXPERIMENTAL

Paclitaxel

Intervention Type DRUG

* Administered intravenously (IV)
* Prescribed at 200 mg/m2 (standard dose)
* Given once every 21 days (i.e., one cycle)
* Up to 4 cycles are administered depending on disease response

Carboplatin

Intervention Type DRUG

* Administered intravenously (IV)
* Prescribed at AUC = 6 using the Cockcroft-Gault formula (standard dose)
* Given once every 21 days (i.e., one cycle)
* Up to 4 cycles are administered depending on disease response

Ascorbic Acid

Intervention Type DRUG

* Administered intravenously (IV)
* 75g per infusion
* Two infusions per week
* 1 cycle is 3 weeks
* given up to 4 cycles
* may be given while chemotherapy if delayed due to low counts

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Paclitaxel

* Administered intravenously (IV)
* Prescribed at 200 mg/m2 (standard dose)
* Given once every 21 days (i.e., one cycle)
* Up to 4 cycles are administered depending on disease response

Intervention Type DRUG

Carboplatin

* Administered intravenously (IV)
* Prescribed at AUC = 6 using the Cockcroft-Gault formula (standard dose)
* Given once every 21 days (i.e., one cycle)
* Up to 4 cycles are administered depending on disease response

Intervention Type DRUG

Ascorbic Acid

* Administered intravenously (IV)
* 75g per infusion
* Two infusions per week
* 1 cycle is 3 weeks
* given up to 4 cycles
* may be given while chemotherapy if delayed due to low counts

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Nov-Onxol Onxol Paclitaxel Novaplus Taxol Amerinet Choice Carboplatin NovaPlus CARBOplatin Paraplatin Paraplatin NovaPlus Pharmacological ascorbate Vitamin C Ascorbate

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* newly diagnosed stage IIIB or IV non -small cell lung cancer. The potential participant must not have received first-line cytotoxic therapy. Prior use of first-line EGFR inhibitors or ALK inhibitors is allowed if there was progression on therapy.
* CNS metastasis is allowed if the metastasis is treated and there are no signs of progression following treatment. The potential participant must be off steroids for at least 3 days and be stable.
* At least 18 years of age
* ECOG performance status of 0, 1, or 2
* absolute neutrophil count (ANC) of at least 1500 cells per mm³
* platelet count of at least 100,000 cells per mm³
* hemoglobin of at least 8 g/dL
* creatinine within 1.5 times the upper limit of normal
* total bilirubin within 1.5 times the upper limit of normal
* ALT within 3 times the institutional upper limit of normal
* AST within 3 times the institutional upper limit of normal
* the participant must tolerate a 15g ascorbate test infusion (screening dose)
* patients who received prior treatment with curative intent must have experienced a treatment-free interval of at least 6 months since the last treatment
* the participant must not be pregnant, be willing to have a pregnancy test done if deemed necessary, and be willing to use adequate birth control during the study
* not breastfeeding
* independently able to provide consent (legally authorized representative and/or power of attorney is not allowed)

Exclusion Criteria

* known sensitizing EGFR mutations or ALK gene rearrangements if the participant has not yet tried EGFR or ALK inhibitor therapies. If the potential participant's biopsy did not allow for gene analysis (inconclusive, not enough tissue), the patient is considered eligible for the study. Enrollment on this clinical trial after progression on targeted therapy is allowed
* 50% or greater PD-L1 expression (patients with unknown PD-L1 expression or when PD-L1 expression can't be determined due to insufficient tumor sample or other reasons remain eligible)
* receiving warfarin therapy and cannot tolerate drug substitution
* active hemoptysis within 1 week of screening (more than 1/2 teaspoon of blood per day)
* actively receiving insulin at the time of ascorbate infusion
* G6PD deficiency
* leptomeningeal disease
* potential participants cannot be on the following drugs: flecainide, methadone, amphetamines, quinidine, or chlorpropamide.
* known active invasive malignancy other than the lung cancer under therapy (non-melanoma skin cancer or carcinoma in situ of the cervix or bladder are exempted)
* potential participants may not enroll in, or be actively receiving treatment from, a therapeutic clinical trial for their cancer. Observational studies (including imaging studies) are acceptable.
* uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness / social situations that would limit compliance with study requirements
* known HIV positive individuals cannot be enrolled in this trial because high-dose ascorbate is a known CYP450 3A4 inducer, which results in lower serum levels of antiretroviral agents

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No